{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:26:39Z","timestamp":1757611599809,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104675","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:31:44Z","timestamp":1753360304000},"page":"104675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligometastatic head and neck cancer: Navigating patient trajectories and broader implications"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-496X","authenticated-orcid":false,"given":"Juliette","family":"Thariat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihane","family":"Lehyanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Boisselier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouchka","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Thureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoann","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Shan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2025.104675_bib0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2022.10.023","article-title":"Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (Gortec 2010-02)","volume":"178","author":"Racadot","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104675_bib0115","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2017.76.2518","article-title":"Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the Gortec 2007-01 phase III randomized trial","volume":"36","author":"Tao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0120","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2017.76.2591","article-title":"Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the Gortec 2007-02 phase III randomized trial","volume":"36","author":"Geoffrois","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0125","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1200\/JCO.2007.15.0102","article-title":"Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma","volume":"26","author":"Janot","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0135","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.ijrobp.2024.11.084","article-title":"Survival without quality of life deterioration in the Gortec 2014-04 \u201cOmet\u201d randomized phase 2 trial in patients with head and neck cancer with oligometastases using stereotactic ablative radiation therapy (SABR) alone or CHemotherapy and SABR","volume":"121","author":"Thariat","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104675_bib0140","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canrad.2023.03.004","article-title":"Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: role of locoregional radiotherapy and metastasis-directed radiotherapy","volume":"28","author":"Tonneau","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104675_bib0150","doi-asserted-by":"crossref","first-page":"107085","DOI":"10.1016\/j.oraloncology.2024.107085","article-title":"Management of oligometastatic head and neck squamous cell carcinoma: A systematic review","volume":"159","author":"Lehyanti","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0155","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104675_bib0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0165","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2025.104675_bib0170","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1200\/JCO.22.02776","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"41","author":"Osoba","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0175","doi-asserted-by":"crossref","first-page":"105509","DOI":"10.1016\/j.oraloncology.2021.105509","article-title":"Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery","volume":"121","author":"Wright","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0180","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.canrad.2021.04.005","article-title":"A priori quality assurance using a benchmark case of the randomized phase 2 Gortec 2014-14 in oligometastatic head and neck cancer patients","volume":"25","author":"Khalladi","year":"2021","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104675_bib0185","doi-asserted-by":"crossref","first-page":"110726","DOI":"10.1016\/j.radonc.2025.110726","article-title":"Cost-minimization analysis of the Gortec 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer","volume":"204","author":"Nerich","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104675_bib0190","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0140-6736(05)60774-X","article-title":"Postoperative radiotherapy in non-small-cell lung cancer","volume":"352","author":"Machtay","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104675_bib0195","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104675_bib0200","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (Keynote-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104675_bib0205","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.3390\/cancers14163894","article-title":"Oligometastatic head and neck cancer: challenges and perspectives","volume":"14","author":"Bahig","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2025.104675_bib0210","first-page":"251","article-title":"The potential for liquid biopsies in head and neck cancer","volume":"25","author":"Spector","year":"2018","journal-title":"Discov Med"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:40:44Z","timestamp":1756932044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825000915"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104675","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oligometastatic head and neck cancer: Navigating patient trajectories and broader implications","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104675"}}